

# Robotic-assisted platform feasible in peripheral artery disease

23 September 2016



favorably. There were no robotic system-associated adverse events.

"These data demonstrate the feasibility and safety of using a robotic-assisted platform for performing peripheral arterial revascularization," the authors write.

The study was funded by Corindus Vascular Robotics.

**More information:** [Full Text \(subscription or payment may be required\)](#)  
[Editorial \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

(HealthDay)—A robotic-assisted platform is safe and feasible for peripheral vascular intervention in patients with peripheral artery disease (PAD), according to a study published online Sept. 14 in *JACC: Cardiovascular Interventions*.

In a prospective single-arm trial, Ehtisham Mahmud, M.D., from the University of California in San Diego, and colleagues examined the feasibility and safety of a robotic-assisted platform for treating PAD. Patients with symptomatic PAD affecting the femoropoplital artery were enrolled; the 20 subjects had primarily Rutherford class 2 to 3 (90 percent) symptoms.

The researchers found that 29 lesions were treated, with 89.7 percent located in the superficial femoral artery. One hundred percent success was reported for device technical success, device safety, and clinical procedural success; 34.5 percent of lesions required provisional stenting. Relative to studies in similar patient cohorts, fluoroscopy time and contrast use compared

APA citation: Robotic-assisted platform feasible in peripheral artery disease (2016, September 23)  
retrieved 21 April 2021 from  
<https://medicalxpress.com/news/2016-09-robotic-assisted-platform-feasible-peripheral-artery.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*